Volume | 1,687,006 |
|
|||||
News | - | ||||||
Day High | 0.9449 | Low High |
|||||
Day Low | 0.8533 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.9002 | 0.8533 | 0.9449 | 0.8925 | 0.913 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,657 | 1,687,006 | $ 0.8978224 | $ 1,514,632 | - | 0.75 - 140.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:58:37 | 25 | $ 0.8799 | USD |
Sunshine Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
22.85M | 25.68M | - | 24.09M | -4.51M | -0.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sunshine Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.9227 | 1.08 | 0.81 | 0.9679466 | 6,372,739 | -0.0388 | -4.21% |
1 Month | 8.50 | 8.50 | 0.75 | 3.16 | 10,570,820 | -7.62 | -89.60% |
3 Months | 6.60 | 14.25 | 0.75 | 7.79 | 26,714,295 | -5.72 | -86.61% |
6 Months | 27.31 | 31.86 | 0.75 | 7.90 | 13,141,014 | -26.43 | -96.76% |
1 Year | 52.65 | 140.00 | 0.75 | 11.93 | 6,849,093 | -51.77 | -98.32% |
3 Years | 275.00 | 987.00 | 0.75 | 167.97 | 4,590,890 | -274.12 | -99.68% |
5 Years | 275.00 | 987.00 | 0.75 | 167.97 | 4,590,890 | -274.12 | -99.68% |
Sunshine Biopharma Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |